Neurizon Therapeutics Limited has released a press release.
Arrival of additional MPL tablets
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust launches international CEO search
- MND Trial Completes Enrolment of Cohort 2
- Stable Patient in MND trial reaches 6-months on MPL
- Canine Cancer Trial Update
- Interim analysis recommended in MND trial
Later from Neurizon Therapeutics
- MND Trial Successfully Completes Second Patient Cohort
- PharmAust Raises $2.5m via Placement
- MPL has anti-cancer effects across multiple cancer types
- Independent tests show MPL retains long-term shelf-life
- Progress update on Phase 1/2 MND interim analysis
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics